Cevian Capital Lifts Smith & Nephew Stake Above 12% in June 2026
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Smith & Nephew Snats ( (SNN) ) has issued an update.
On 8 June 2026, activist investor Cevian Capital II GP Limited increased its indirect holding in Smith & Nephew to 12.07% of the company’s voting rights, up from 11.18%, according to a major holdings notification filed with regulators. The stake, held via funds for which Cevian acts as general partner and registered in the name of Aurora Nominees on behalf of UBS as custodian, underscores growing shareholder influence over the medical device maker’s strategic direction and could signal mounting pressure on management ahead of future governance or operational decisions.
Cevian’s enlarged position, amounting to 102,493,881 voting rights, was formally notified to Smith & Nephew on 10 June 2026 and completed in Jersey the same day, consolidating the investor’s status as a leading shareholder. While the filing contains no explicit demands, the move is likely to be interpreted by stakeholders as a prelude to more active engagement on issues such as portfolio focus, margin improvement and capital allocation at the FTSE-listed group.
The most recent analyst rating on (SNN) stock is a Hold
with a $30.00 price target.
To see the full list of analyst forecasts on Smith & Nephew Snats stock,
see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock,
click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based medical technology company listed in London and the U.S., best known for orthopaedic reconstruction, sports medicine, and advanced wound management products used in hospitals and clinics worldwide. Its shares are widely held by international institutional investors, making changes in significant shareholdings closely watched by the market.
Average Trading Volume: 1,075,797
Technical Sentiment Signal: Buy
Current Market Cap: $13.18B
Find detailed analytics on SNN stock on TipRanks’ Stock Analysis page.
